Literature DB >> 18769633

Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis.

Laure Michel1, Laureline Berthelot, Ségolène Pettré, Sandrine Wiertlewski, Fabienne Lefrère, Cécile Braudeau, Sophie Brouard, Jean-Paul Soulillou, David-Axel Laplaud.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease that results in demyelination in the central nervous system, and a defect in the regulatory function of CD4+CD25high T cells has been implicated in the pathogenesis of the disease. Here, we reanalyzed the function of this T cell subset in patients with MS, but we depleted cells expressing IL-7 receptor alpha-chain (CD127), a marker recently described as present on activated T cells but not Tregs. Similar to other studies, we observed a marked defect in the suppressive function of unseparated CD4+CD25high T cells isolated from MS patients. However, when CD127(high) cells were removed from the CD4+CD25high population, patient and control cells inhibited T cell proliferation and cytokine production equally. Likewise, when the CD25 gate used to sort the cells was stringent enough to eliminate CD127high cells, CD4+CD25high T cells from patients with MS and healthy individuals had similar regulatory function. Additional analysis indicated that the CD127high cells within the CD4+CD25high T cell population from patients with MS appeared more proliferative and secreted more IFN-gamma and IL-2 than the same cells from healthy individuals. Taken together, we conclude that CD4+CD25highCD127low Tregs from MS patients and healthy individuals exhibit similar suppressive functions. The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769633      PMCID: PMC2525698          DOI: 10.1172/JCI35365

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

5.  An essential role for Scurfin in CD4+CD25+ T regulatory cells.

Authors:  Roli Khattri; Tom Cox; Sue-Ann Yasayko; Fred Ramsdell
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression.

Authors:  Koen Venken; Niels Hellings; Tom Broekmans; Karen Hensen; Jean-Luc Rummens; Piet Stinissen
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.

Authors:  Prabhakar Putheti; Asa Pettersson; Mats Soderstrom; Hans Link; Yu Min Huang
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

8.  Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.

Authors:  D Dieckmann; H Plottner; S Berchtold; T Berger; G Schuler
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  50 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

2.  IL-7 induces clathrin-mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells.

Authors:  Elliott M Faller; Feras M Ghazawi; Marko Cavar; Paul A MacPherson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

3.  IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.

Authors:  Lyssia Belarif; Richard Danger; Laetitia Kermarrec; Véronique Nerrière-Daguin; Sabrina Pengam; Tony Durand; Caroline Mary; Elise Kerdreux; Vanessa Gauttier; Aneta Kucik; Virginie Thepenier; Jerome C Martin; Christie Chang; Adeeb Rahman; Nina Salabert-Le Guen; Cécile Braudeau; Ahmed Abidi; Grégoire David; Florent Malard; Celine Takoudju; Bernard Martinet; Nathalie Gérard; Isabelle Neveu; Michel Neunlist; Emmanuel Coron; Thomas T MacDonald; Pierre Desreumaux; Hoa-Le Mai; Stephanie Le Bas-Bernardet; Jean-François Mosnier; Miriam Merad; Régis Josien; Sophie Brouard; Jean-Paul Soulillou; Gilles Blancho; Arnaud Bourreille; Philippe Naveilhan; Bernard Vanhove; Nicolas Poirier
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

Review 4.  Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Authors:  Jonathan H Esensten; David Wofsy; Jeffrey A Bluestone
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

5.  Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells.

Authors:  Irina V Pinchuk; Ellen J Beswick; Jamal I Saada; Gushyalatha Boya; David Schmitt; Gottumukkala S Raju; Julia Brenmoehl; Gerhard Rogler; Victor E Reyes; Don W Powell
Journal:  Gastroenterology       Date:  2011-03-02       Impact factor: 22.682

6.  FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Authors:  F Sellebjerg; M Krakauer; M Khademi; T Olsson; P S Sørensen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.

Authors:  M C González-Oria; M Márquez-Coello; J A Girón-Ortega; J Argente; M Moya; José-Antonio Girón-González
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-16       Impact factor: 4.147

8.  MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis.

Authors:  Mary E Severin; Priscilla W Lee; Yue Liu; Amanda J Selhorst; Matthew G Gormley; Wei Pei; Yuhong Yang; Mireia Guerau-de-Arellano; Michael K Racke; Amy E Lovett-Racke
Journal:  Brain       Date:  2016-04-28       Impact factor: 13.501

Review 9.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?

Authors:  Benjamin Wilde; Marielle Thewissen; Jan Damoiseaux; Pieter van Paassen; Oliver Witzke; Jan Willem Cohen Tervaert
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

10.  Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system.

Authors:  Nalini Kumar Vudattu; Sharon Kuhlmann-Berenzon; Mohsen Khademi; Vicki Seyfert; Thomas Olsson; Markus J Maeurer
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.